natgillin/translations-raw huggingface dataset:
Drug-related adverse reactions were more common in APV20003 (57%) where subjects received once daily fosamprenavir / ritonavir when compared to APV29005 (33%) where subjects received twice daily fosamprenavir / ritonavir. 
Nuspojave povezane s lijekom bile su učestalije u ispitivanju APV20003 (57%) tijekom kojeg su ispitanici primali fosamprenavir/ritonavir jednom dnevno nego li u ispitivanju APV29005 (33%) tijekom kojeg su ispitanici primali fosamprenavir/ritonavir 2 puta dnevno.
In the paediatric studies APV20003 and APV29005, 77 PI-experienced patients were treated with fosamprenavir / ritonavir-based regimens and 43 patients met study-defined virologic failure criteria through 48 weeks in APV29005 and up to 108 weeks in APV20003. 
U pedijatrijskim ispitivanjima APV20003 i APV29005, 77 bolesnika koji su ranije primali IP terapiju liječeno je režimima koji su sadržavali fosamprenavir/ritonavir; a 43 bolesnika zadovoljila su utvrđene kriterije za virološki neuspjeh tijekom 48 tjedana u ispitivanju APV29005 te do 108 tjedana u ispitivanju APV20003.
Any unused medicinal product should be disposed of in accordance with local requirements. 
Neiskorišteni lijek ili otpadni materijal potrebno je zbrinuti sukladno nacionalnim propisima.
Sixteen of 434 ART-naïve patients who received fosamprenavir 700 mg/ritonavir 100 mg twice daily in ESS100732 experienced virological failure by Week 48 with 14 isolates genotyped. 
16 od 434 bolesnika koji ranije nisu primali antiretrovirusnu terapiju, a koji su primili fosamprenavir 700 mg/ritonavir 100 mg 2 puta dnevno u ESS100732 do 48. tjedna imalo je virološki neuspjeh s 14 genotipiziranih izolata.
Signs to look out for include: 
Znakovi na koje treba paziti uključuju: • ukočenost zglobova
High doses (> 200 mg/day) of ketoconazole or itraconazole are not recommended. 
(> 200 mg/dan) ketokonazola ili itrakonazola.
In the pivotal studies of Telzir, in patients receiving fosamprenavir with ritonavir there was no evidence of an increased risk of rashes in patients with a history of sulphonamide allergy versus those who did not have a sulphonamide allergy. 
U ključnim ispitivanjima lijeka Telzir nije dokazan povećani rizik za razvijanje osipa kod bolesnika koji primaju fosamprenavir s ritonavirom, neovisno o tome jesu li u anamnezi imali alergiju na sulfonamide naspram onih koji je nisu imali.
Rat pups exposed pre and post-natally to amprenavir and fosamprenavir showed developmental toxicity (see section 5.3). 
Mladunčad štakora koja je pre- i postnatalno bila izložena amprenaviru i fosamprenaviru pokazala je razvojnu toksičnost (vidjeti dio 5.3).
No drug interaction studies. 
Nije bilo ispitivanja interakcija lijeka.
Herbal preparations containing St John's wort must not be combined with Telzir (see section 4.3). 
Biljni pripravci koji sadrže Gospinu travu ne smiju se kombinirati s lijekom Telzir (vidjeti dio 4.3).
Didanosine gastro-resistant capsule 
Didanozin želučanootporna kapsula
For children weighing less than 39 kg, Telzir oral suspension is the recommended option for the most accurate dosing in children based on body weight (please refer to the Summary of Product Characteristics for Telzir oral suspension). 
Za djecu čija je tjelesna težina manja od 39 kg, u svrhu što ispravnijeg doziranja temeljem tjelesne težine, preporučuje se primjena Telzir oralne suspenzije (potrebno vidjeti sažetak opisa svojstava lijeka za Telzir oralnu suspenziju).
You must check the list of medicines under 'Don't take Telzir' at the beginning of section 2 of this leaflet. 
"Nemojte uzimati Telzir" na početku dijela 2 ove Upute o lijeku.
Additional mutations observed which may contribute to resistance were: L10V/F/R, I13V, K20R/T, L33F/V, M36I, M46I/L, I47V/L Q58E, I62V, L63P, V77I, I85V, and I93L. 
Dodatne zamijećene mutacije koje mogu doprinijeti rezistenciji bile su: L10V/F/R, I13V, K20R/T, L33F/V, M36I, M46I/L, I47V/L Q58E, I62V, L63P, V77I, I85V i I93L.
Among the 81 PI-naïve paediatric patients treated with fosamprenavir / ritonavir, 15 patients met protocol-defined virological failure through 48 weeks in APV29005 and up to 108 weeks in APV20003. 
Od 81 pedijatrijskog bolesnika liječenog fosamprenavirom/ritonavirom koji ranije nije primao IP terapiju, u njih 15 zabilježen je protokolom definiran virološki neuspjeh tijekom 48 tjedana u ispitivanju APV29005 te do 108 tjedana u ispitivanju APV20003.
Hepatitis C virus (HCV) Direct-Acting Antivirals: When hepatitis C virus direct-acting antiviral (DAA) drugs, which are metabolised by CYP3A4 or are inducers/inhibitors of CYP3A4, are coadministered with fosamprenavir/ritonavir, altered plasma concentrations of medications are expected due to inhibition or induction of CYP3A4 enzyme activity (see sections 4.3 and 4.5). 
Antivirotici koji djeluju izravno na virus hepatitisa C (HCV): Kada se istodobno s fosamprenavirom/ritonavirom primjenjuju antivirotici koji djeluju izravno na virus hepatitisa C, a koji se metaboliziraju putem CYP3A4 ili inhibiraju/induciraju CYP3A4, očekuje se da će se promijeniti koncentracije lijekova u plazmi zbog inhibicije ili indukcije aktivnosti enzima CYP3A4 (vidjeti dijelove 4.3 i 4.5).
The relevance of the hepatocellular findings in the rodents for humans is uncertain; however, there is no evidence from clinical trials or marketed use to suggest that these findings are of clinical significance. 
Značaj hepatocelularnih nalaza kod glodavaca za ljude nije poznat, međutim, iz kliničkih ispitivanja ili podataka nakon stavljanja lijeka u promet ne postoje dokazi koji bi upućivali da ti nalazi imaju klinički značaj.
Because there may be an increased risk of hepatic transaminase elevations and hormonal levels may be altered with co-administration of fosamprenavir, ritonavir and oral contraceptives, alternative nonhormonal methods of contraception are recommended for women of childbearing potential (see section 4.5). 
Budući da pri istodobnoj primjeni fosamprenavira, ritonavira i oralnih kontraceptiva može postojati povećan rizik za povišenje razina jetrenih transaminaza i razina hormona, ženama reproduktivne dobi preporučuje se primjena drugih, nehormonalnih kontracepcijskih metoda (vidjeti dio 4.5).
25-O-desacetylrifabutin: AUC(0-48) ↑ 11-fold* *compared to rifabutin 300 mg once daily 
25-O-desacetilrifabutin: AUC(048) ↑ 11 puta* *u usporedbi s rifabutinom 300 mg jednom dnevno
No dosage adjustment necessary with antacids, proton-pump inhibitors or histamine H2 receptor antagonists. 
S antacidima, inhibitorima protonske pumpe ili antagonistima histaminskih H2 receptora nije potrebno prilagođavanje doze.
In animal studies at systemic plasma exposures (AUC) to amprenavir lower than therapeutic exposure in patients treated with Telzir, some developmental toxicity was observed (see section 5.3). 
Ispitivanja na životinjama pokazala su da se pri sistemskoj izloženosti plazme (AUC) amprenaviru, u vrijednostima nižim od terapijske izloženosti u bolesnika liječenih lijekom Telzir, kod određenoj mjeri javlja razvojna toksičnost (vidjeti dio 5.3).
Shake the bottle for 20 seconds before the first use. 
Prije prve primjene, protresite bočicu tijekom 20 sekundi.
The adverse reaction profile was similar across all the respective adult studies: antiretroviral naïve patients (APV30002, ESS100732), protease inhibitor experienced (twice daily dosing, APV30003) patients. 
Profil nuspojava bio je sličan u svim ispitivanjima provedenim kod odraslih, i kod bolesnika koji ranije nisu primali antiretrovirotike (APV30002, ESS100732) i kod bolesnika koji su ranije primali inhibitore proteaze (doziranje 2 puta dnevno, APV30003).
No studies have been done on the use of Telzir/ritonavir with other hormonal therapies, such as hormone replacement therapy (HRT). 
Nisu se provodila ispitivanja lijeka Telzir/ritonavira u kombinaciji s drugim hormonskim terapijama, poput hormonske nadomjesne terapije.
Autoimmune disorders (such as Graves' disease) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and can occur many months after initiation of treatment. 
U uvjetima imunološke reaktivacije prijavljeni su i autoimuni poremećaji (poput Gravesove bolesti i autoimunog hepatitisa); međutim, prijavljeno vrijeme do nastupa bolesti je varijabilno pa se ona može javiti i mjesecima nakon uvođenja liječenja.
Subjects (%) with plasma HIV-1 RNA <50 copies/ml Subjects (%) with plasma HIV-1 RNA <400 copies/ml Subjects with >1 log10 change from baseline in plasma HIV1 RNA Change from baseline in CD4 cells (cells/µl) 
Ispitanici (%) s HIV-1 RNK u plazmi <50 kopija/ml Ispitanici (%) s HIV-1 RNK u plazmi <400 kopija/ml Ispitanici s promjenom HIV-1 RNK u plazmi >1 log10 od početnih vrijednosti
Compared to the historical adult population receiving fosamprenavir / ritonavir 700 / 100 mg twice daily, 12 to 18 year old subjects had 20 % lower plasma APV AUC(024), 23 % lower Cmax, and 20 % lower Cmin values. 
U usporedbi s ranijim podacima o odrasloj populaciji koja je primala fosamprenavir/ritonavir 700/100 mg 2 puta dnevno, ispitanici od 12 do 18 godina imali su 20% niže vrijednosti APV AUC(0-24) u plazmi, 23% nižu vrijednost Cmax, i 20% nižu vrijednost Cmin.
Amprenavir: ↓ expected (Modest CYP3A4 induction) 
Amprenavir: očekuje se ↓ (Blaga indukcija CYP3A4)
Telzir helps to control your condition, but it is not a cure for HIV infection. 
Održavajte redovite kontakte sa svojim liječnikom Telzir pomaže u držanju Vašeg stanja pod kontrolom, ali neće izliječiti HIV infekciju.
After oral administration, fosamprenavir is rapidly and almost completely hydrolysed to amprenavir and inorganic phosphate prior to reaching the systemic circulation. 
Nakon peroralne primjene fosamprenavir se, prije dolaska u sistemski krvotok, brzo i gotovo u cijelosti hidrolizira na amprenavir i anorganske fosfate.
Various regimens have been assessed in the amprenavir/fosamprenavir development programs with and without co-administration of ritonavir. 
U razvojnim programima amprenavira/fosamprenavira ispitivali su se različiti režimi terapije, s ili bez istodobne primjene ritonavira.
Telzir/ritonavir should not be co-administered with orally administered midazolam (see section 4.3), whereas caution should be used with co-administration of Telzir/ritonavir and parenteral midazolam. 
Telzir/ritonavir ne smiju se primijeniti istodobno s midazolamom primijenjenim oralno (vidjeti dio 4.3), dok se u slučaju primjene parenteralnim putem, midazolam može, uz mjere opreza, primijeniti istodobno s lijekom Telzir/ritonavirom.
Ketoconazole: Cmax ↑ 25% Ketoconazole: AUC ↑ 2.69fold. 
Ketokonazol: Cmax ↑ 25% Ketokonazol: AUC ↑ 2,69 puta.
All Subjects 
Svi ispitanici
These products may cause an allergic reaction in some individuals. 
U nekih osoba te tvari mogu uzrokovati alergijsku reakciju koja može biti odgođena.
Drugs by Therapeutic Area Interaction 
Lijekovi prema terapijskom području
Telzir 700 mg film-coated tablets Fosamprenavir 
Telzir 700 mg filmom obložene tablete fosamprenavir
6-17 years >39 kg Tablet or Oral suspension 700 mg (1 tablet or 14 ml suspension) 
>39 kg Tablete ili oralna suspenzija 700 mg (1 tableta ili 14 ml suspenzije)
≤ 200 mg once daily 
≤ 200 mg jednom dnevno
The recommended dose is 0.36 ml/kg of Telzir oral suspension (18 mg per kg fosamprenavir) twice daily with 3 mg/kg ritonavir oral solution twice daily. 
Preporučena doza je 0,36 ml/kg Telzir oralne suspenzije dva puta dnevno (18 mg/kg fosamprenavira) dva puta dnevno s 3 mg/kg oralne otopine ritonavira dva puta dnevno.
The mutational profiles were similar to those described for PIexperienced adults treated with fosamprenavir / ritonavir. 
Profili mutacija bili su slični onima opisanim kod odraslih bolesnika liječenih fosamprenavirom/ritonavirom, a koji su ranije primali IP terapiju.
The use of Telzir concomitantly with halofantrine or lidocaine (systemic) is not recommended (see section 4.5). 
Ne preporučuje se istodobna primjena lijeka Telzir s halofantrinom ili lidokainom (sistemskim) (vidjeti dio 4.5).
methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216). 
metilparahidroksibenzoat (E218), propilparahidroksibenzoat (E216).
No new safety concerns were identified from analyses of 48 week data from studies APV29005 or APV20002, in which 54 subjects 4 weeks to <2 years of age received twice daily fosamprenavir / ritonavir with background nucleoside reverse transcriptase inhibitor therapy and 5 subjects received only single doses of fosamprenavir with or without ritonavir. 
Nisu identificirana nova sigurnosna pitanja u analizama podataka nakon 48 tjedana iz ispitivanja APV29005 ili APV20002, u kojima su 54 ispitanika u dobi od 4 tjedna do < 2 godine primala fosamprenavir/ritonavir dvaput na dan uz osnovnu terapiju nukleozidnim inhibitorima reverzne transkriptaze, dok je 5 ispitanika primilo samo jednokratnu dozu fosamprenavira s ritonavirom ili bez njega.
400 mg/100 mg twice daily 
400 mg/100 mg 2 puta dnevno
Please refer to the table below for the dosing recommendations in adults. 
Za preporuke doziranja u odraslih molimo pogledajte niže navedenu tablicu.
Very common side effects These may affect more than 1 in 10 people: 
Vrlo česte nuspojave mogu se javiti u više od 1 na 10 osoba:
ViiV Healthcare Trading Services UK Limited 12 Riverwalk, 
ViiV Healthcare Trading Services UK Limited 12 Riverwalk, Citywest Business Campus Dublin 24,
There are insufficient data to recommend the use of fosamprenavir with ritonavir in heavily pre-treated patients. 
Nema dovoljno podataka da bi se preporučila primjena fosamprenavira s ritonavirom kod bolesnika koji su ranije primali snažno antiretrovirusno liječenje.
Remove the bottle cap and keep it safely. 
2. Uklonite zatvarač s boce i pospremite ga.
The median durations of prior exposure to NRTIs were 257 weeks for patients receiving fosamprenavir with ritonavir twice daily (79 % had ≥ 3 prior NRTIs) and 210 weeks for patients receiving lopinavir/ritonavir (64 % had ≥ 3 prior NRTIs). 
Medijan trajanja prethodne izloženosti NRTI bio je 257 tjedana za bolesnike koji su primali fosamprenavir s ritonavirom 2 puta dnevno (79 % imalo je ≥ 3 ranije NRTI) i 210 tjedana za bolesnike koji su primali lopinavir/ritonavir (64 % imalo je ≥ 3 ranije NRTI).
Herbal preparations containing St John's wort (Hypericum perforatum) must not be used while taking Telzir due to the risk of decreased plasma concentrations and reduced clinical effects of amprenavir (see section 4.5). 
Tijekom primjene lijeka Telzir ne smiju se koristiti biljni pripravci koji sadržavaju Gospinu travu (Hypericum perforatum) zbog rizika od smanjenja koncentracije u plazmi i smanjenog kliničkog učinka amprenavira (vidjeti dio 4.5).
Table 5 Baseline Characteristics and Efficacy Outcomes at Week 48 in APV29005 ITT(E) Population 
Tablica 5 Početne značajke i ishodi djelotvornosti u 48. tjednu u ITT(E) populaciji iz ispitivanja APV29005
Paroxetine: Cmax ↓ 51% Paroxetine: AUC ↓ 55% 
Paroksetin: Cmax ↓ 51% Paroksetin: AUC ↓55%
• Headache, feeling dizzy 
• glavobolja, osjećaj omaglice • osjećaj umora
When fosamprenavir and ritonavir are co-administered, the ritonavir metabolic drug interaction profile may predominate because ritonavir is a more potent CYP3A4 inhibitor. 
Kod istodobne primjene fosamprenavira i ritonavira, metabolički profil ritonavira u interakcijama lijekova može biti predominantan budući da je ritonavir potentniji inhibitor
In long-term carcinogenicity studies with fosamprenavir in mice and rats, there were increases in hepatocellular adenomas and hepatocellular carcinomas in mice at exposure levels equivalent to 0.1 to 0.3-fold those in humans given 700 mg of fosamprenavir plus 100 mg ritonavir twice daily, and increases in hepatocellular adenomas and thyroid follicular cell adenomas in rats at exposure levels equivalent to 0.3 to 0.6-fold those in humans given 700 mg of fosamprenavir plus 100 mg ritonavir twice daily. 
U ispitivanjima dugotrajne karcinogenosti fosamprenavira provedenim na miševima i štakorima zamijećeno je povećanje hepatocelularnih adenoma i hepatocelularnih karcinoma kod miševa pri razinama izloženosti ekvivalentnim od 0,1 do 0,3-puta od onih koje nalazimo kod ljudi kod doze od 700 mg fosamprenavira sa 100 mg ritonavira 2 puta dnevno, kao i povećanje hepatocelularnih adenoma i adenoma folikularnih stanica štitnjače kod štakora pri razinama izloženosti od 0,3 do 0,6
If you have moderate or severe liver disease the dose of Telzir has to be lowered. 
Ako bolujete od umjerene ili teške bolesti jetre, doza lijeka
Careful monitoring of the therapeutic and adverse reactions of tricyclic antidepressants is recommended (see section 
Preporučuje se pažljivo praćenje terapijskih reakcija i nuspojava tricikličkih antidepresiva (vidjeti dio 4.4).
The full prescribing information for ritonavir must therefore be consulted prior to initiation of therapy with Telzir with ritonavir. 
Stoga se, prije početka terapije lijekom Telzir s ritonavirom, moraju konzultirati sve informacije o propisivanju ritonavira.
CSF penetration of amprenavir is negligible in humans. 
Prodor amprenavira u cerebrospinalni likvor kod ljudi je zanemariv.
Increased plasma concentrations of quetiapine may lead to coma. 
Povećane koncentracije kvetiapina u plazmi mogu izazvati komu.
Efficacy Outcomes 
Ishodi djelotvornosti
Therapeutic concentration monitoring is recommended for tricyclic antidepressants (e.g. desipramine and nortriptyline) when coadministered with Telzir (see section 4.5). 
Preporučuje se praćenje terapijske koncentracije tricikličkih antidepresiva (npr. desipramina i nortriptilina) kada ih se primjenjuje istodobno s lijekom Telzir (vidjeti dio 4.5).
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON FOR ORAL SUSPENSION 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKA KARTONSKA KUTIJA ZA ORALNU SUSPENZIJU
20 mg once daily 
20 mg jednom dnevno
Reinforced monitoring of the International Normalised Ratio is recommended (see section 4.4). 
Preporučuje se pojačano praćenje Međunarodnog normaliziranog omjera - INR (vidjeti dio 4.4).
Telzir may be less effective due to decreased amprenavir plasma concentrations in patients taking these medicinal products concomitantly (see section 4.5). 
Zbog smanjene koncentracije amprenavira u plazmi, Telzir može biti manje učinkovit kod bolesnika koji istodobno primaju navedene lijekove (vidjeti dio 4.5).
Let them dry completely before you use them again. 
Pazite sa se prije ponovne primjene osuše u potpunosti.
After multiple dose oral administration of fosamprenavir 700 mg with ritonavir 100 mg twice daily, amprenavir was rapidly absorbed with a geometric mean (95 % CI) steady state peak plasma amprenavir concentration (Cmax) of 6.08 (5.38-6.86) µg/ml occurring approximately 1.5 (0.75-5.0) hours after dosing (tmax). 
Nakon peroralne primjene višestrukih doza fosamprenavira od 700 mg s ritonavirom od 100 mg 2 puta dnevno amprenavir je brzo apsorbiran s geometrijskom srednjom vrijednosti (95% CI) vršne koncentracije amprenavira u plazmi pri stanju dinamičke ravnoteže (Cmax) od 6,08 (5,38-6,86) µg/ml do koje dolazi oko 1,5 (0,75-5,0) sati nakon doziranja (tmax).
Telzir tablet is administered orally. 
Tablete Telzir primjenjuju se peroralno.
Rhabdomyolysis: an increase in CPK, myalgia, myositis, and rarely, rhabdomyolysis, have been reported with protease inhibitors, more specifically in association with nucleoside analogues. 
Rabdomioliza: pri korištenju inhibitora proteaze, više specifično s analozima nukleozida, prijavljene su povećane vrijednosti CPK, mialgija, miozitis i rijetko rabdomioliza.
Increased concentrations of HMG-CoA reductase inhibitors may cause myopathy, including rhabdomyolysis. 
Povećane koncentracije inhibitora HMG-CoA reduktaze mogu uzrokovati miopatiju,
Other oral anticoagulants 
Drugi oralni antikoagulansi
• desipramine, nortriptyline, paroxetine and similar medicines (used to treat depression) 
• dolutegravir (koristi se za liječenje infekcije HIV-om) • dezipramin, nortriptilin, paroksetin i slične lijekove (koriste se za liječenje depresije)
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON FOR TABLETS 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKA KARTONSKA KUTIJA ZA TABLETE
Phenytoin: Cmax ↓ 20% Phenytoin: AUC ↓ 22% Phenytoin: Cmin ↓ 29% 
Fenitoin: Cmax ↓ 20% Fenitoin: AUC ↓ 22% Fenitoin: Cmin ↓ 29%
Telzir 50 mg/ml oral suspension Fosamprenavir 
Telzir 50 mg/ml oralna suspenzija fosamprenavir
Amprenavir: Cmax ↓ 13%* Amprenavir: AUC ↓ 26%* Amprenavir: Cmin ↓ 42 %* * compared to fosamprenavir / ritonavir 700 mg/100 mg twice daily 
Amprenavir: Cmax ↓ 13%* Amprenavir: AUC ↓ 26%* Amprenavir: Cmin ↓ 42 %* * u usporedbi s fosamprenavirom / ritonavirom 700 mg/100 mg 2 puta dnevno
Fosamprenavir tablets and oral suspension with ritonavir in combination with NRTIs have been evaluated in protease inhibitor naïve and experienced children and adolescent patients. 
Tablete i oralna suspenzija fosamprenavira s ritonavirom u kombinaciji s NRTI procjenjivani su kod dječjih i adolescentnih bolesnika i kod onih koji su primali i kod onih koji nisu ranije primali terapiju inhibitora proteaze.
Administration of fosamprenavir 700 mg twice daily with ritonavir 100 mg twice daily results in plasma amprenavir concentrations (data from study APV30003 in antiretroviral experienced patients) which results in protein adjusted median ratios of Cmin/IC50 and Cmin/IC95 of 21.7 (range 1.19-240) and 3.21 (range 0.26-30.0), respectively. 
Primjena fosamprenavira u dozi od 700 mg 2 puta dnevno s ritonavirom u dozi od 100 mg 2 puta dnevno rezultira koncentracijama amprenavira u plazmi (podaci iz ispitivanja APV30003 na bolesnicima koji su ranije primali antiretrovirusnu terapiju) koja dovodi do prilagođenog proteinskog medijana u omjeru Cmin/IC50 i Cmin/IC95 od 21,7 (raspon 1,19-240) odnosno 3,21 (raspon 0,26-30,0).
Table 1 Efficacy Outcome at Week 48 in ESS100732 (ART-Naïve Patients) 
Tablica 1 Ishod djelotvornosti u 48. tjednu u ESS100732 (bolesnici koji nisu ranije primali antiretrovirusnu terapiju)
18 mg/kg (0.36 ml/kg ); maximum 700 mg or 14 ml 
33-38 kg Oralna suspenzija 18 mg/kg (0,36 ml/kg ); najviše 700 mg ili 14 ml Oralnu suspenziju treba uzimati s hranom
In case of concomitant administration with antineoplastic agents metabolized by CYP3A, please refer to the relevant product information for these medications. 
U slučaju istodobne primjene s antineoplasticima koji se metaboliziraju putem CYP3A, potrebno je vidjeti sažetak opisa svojstava lijeka za te lijekove.
Co-administration of Telzir 700 mg twice daily with ritonavir in doses greater than 100 mg twice daily has not been clinically evaluated. 
Istodobna primjena lijeka Telzir od 700 mg dva puta dnevno s dozama ritonavira većim od 100 mg, dva puta na dan, nije klinički ispitana.
When antineoplastic agents that are metabolised by CYP3A are co-administered with fosamprenavir/ritonavir, plasma concentrations of these antineoplastic medications may be increased and could increase the risk of adverse events usually associated with these antineoplastic agents. 
Kada se istodobno s fosamprenavirom/ritonavirom primjenjuju antineoplastici koji se metaboliziraju putem CYP3A, može se povećati koncentracija antineoplastika u plazmi, što može povećati rizik od štetnih događaja koje se obično povezuje s tim antineoplasticima.
In addition, decreased number of implantation sites per litter and a prolongation of gestation were seen when pups were mated after reaching maturity. 
Nadalje, pri parenju mladunčadi nakon dosezanja odrasle dobi, zamijećen je smanjeni broj mjesta implantacije po leglu te produljenja gestacije.
Telzir with ritonavir must not be co-administered with medicinal products with narrow therapeutic windows that are highly dependent on CYP2D6 metabolism, e.g. flecainide and propafenone (see section 4.5). 
Telzir s ritonavirom ne smije se istodobno primjenjivati s lijekovima koji imaju usku terapijsku širinu, a koji su visoko ovisni o metabolizmu putem CYP2D6, poput flekainida i propafenona (vidjeti dio